Sangamo Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 405

Market Cap: $170.2M

Website

Introduction: Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

Clinical Trials

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

Phase 1

Terminated

Conditions: Mucopolysaccharidosis II
MPS II

Interventions: Biological: SB-913

First Posted Date: 2017-02-02

Last Posted Date: 2022-10-25

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 9

Registration Number: NCT03041324

Locations: 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸
NYU School of Medicine, Neurogenetics Division, New York, New York, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States

and more 2 locations

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I

Phase 1

Terminated

Conditions: MPS I

Interventions: Biological: SB-318

First Posted Date: 2016-03-08

Last Posted Date: 2023-01-26

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 3

Registration Number: NCT02702115

Locations: 🇺🇸
UCSF Benioff Children's Hospital Oakland, Oakland, California, United States

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Phase 1

Terminated

Conditions: Hemophilia B

Interventions: Biological: SB-FIX

First Posted Date: 2016-03-01

Last Posted Date: 2024-07-19

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 1

Registration Number: NCT02695160

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Genetic: SB-728mR-T
Drug: Cyclophosphamide

First Posted Date: 2014-08-26

Last Posted Date: 2021-03-19

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 8

Registration Number: NCT02225665

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

Phase 1

Completed

Conditions: HIV

Interventions: Genetic: SB-728-T

First Posted Date: 2012-03-02

Last Posted Date: 2021-05-24

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 26

Registration Number: NCT01543152

Locations: 🇺🇸
UCLA Care Center, Los Angeles, California, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Circle CARE Center, LLC, Norwalk, Connecticut, United States

and more 8 locations

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Phase 1

Completed

Conditions: HIV Infection
HIV

Interventions: Biological: SB-728-T

First Posted Date: 2010-12-03

Last Posted Date: 2019-09-20

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 21

Registration Number: NCT01252641

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Orange Coast Medical Group, Newport Beach, California, United States
🇺🇸
UCLA CARE Center, Los Angeles, California, United States

and more 1 locations

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetic Polyneuropathy

Interventions: Drug: SB-509
Other: Saline

First Posted Date: 2010-03-03

Last Posted Date: 2022-05-23

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 170

Registration Number: NCT01079325

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients

Phase 1

Completed

Conditions: HIV Infection
HIV Infections

Interventions: Genetic: SB-728-T

First Posted Date: 2010-01-08

Last Posted Date: 2015-03-13

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 19

Registration Number: NCT01044654

Locations: 🇺🇸
Central West Clinical Research, Inc., St Louis, Missouri, United States
🇺🇸
Southwest CARE Center, Santa Fe, New Mexico, United States
🇺🇸
Gordon Crofoot, MD, PA, Houston, Texas, United States

and more 6 locations

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

Phase 1

Completed

Conditions: Idiopathic Parkinson's Disease

Interventions: Procedure: Sham Surgery

First Posted Date: 2009-09-28

Last Posted Date: 2020-04-16

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 57

Registration Number: NCT00985517

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
Stanford School of Medicine, Palo Alto, California, United States

and more 8 locations

Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Procedure: Placebo Surgery

First Posted Date: 2009-04-07

Last Posted Date: 2020-12-21

Lead Sponsor: Sangamo Therapeutics

Target Recruit Count: 49

Registration Number: NCT00876863

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States
🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of Alabama, Birmingham, Alabama, United States

and more 7 locations

Home Terms & Conditions Privacy Policy